Similarly, the increase in V2-receptor expression, which is induced by HSP90 inhibitors, is also seen in people: hyponatraemia is a side effect that was frequently observed in cancer patients undergoing clinical trials with various HSP90 inhibitors [103]. This evidence concerns the gene HSP90AA1 and cancer.